Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Rx Compounding Ad Restrictions May Be Unnecessary, Justices Say

Executive Summary

FDA restrictions on advertising compounded drugs may not be justified given the additional safeguards provided under the FDA Modernization Act, U.S. Supreme Court justices suggested during oral arguments in Thompson v. Western States Medical Center Feb. 26
Advertisement

Related Content

Supreme Court Reaffirms Least Restrictive Standard For Ad Controls
Supreme Court Reaffirms Least Restrictive Standard For Ad Controls
Pharmacy Compounding Could Be Added To PDUFA III, APhA’s Winckler Says
Pharmacy Compounding Could Be Added To PDUFA III, APhA’s Winckler Says
FDA Enforcing Rx Compounding Regs Pending Supreme Court Ruling
Pharmacy Compounding Disclaimer May Be Alternative To FDAMA, Court Says
Pharmacy Compounding Disclaimer May Be Alternative To FDAMA, Court Says
Advertisement
UsernamePublicRestriction

Register

PS039399

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel